CR20230309A - ANTICUERPOS MULTIESPECÍFICOS QUE TIENEN ESPECIFICIDAD PARA IL-4R e IL-31 - Google Patents

ANTICUERPOS MULTIESPECÍFICOS QUE TIENEN ESPECIFICIDAD PARA IL-4R e IL-31

Info

Publication number
CR20230309A
CR20230309A CR20230309A CR20230309A CR20230309A CR 20230309 A CR20230309 A CR 20230309A CR 20230309 A CR20230309 A CR 20230309A CR 20230309 A CR20230309 A CR 20230309A CR 20230309 A CR20230309 A CR 20230309A
Authority
CR
Costa Rica
Prior art keywords
multispecific antibody
nucleic acids
present
specificity
multispecific antibodies
Prior art date
Application number
CR20230309A
Other languages
English (en)
Inventor
Alexandre Simonin
Tea Gunde
Maria Johansson
Yoshihide Miyake
Stefan Warmuth
Julia Tietz
Noriko Shiraishi
Yoshio Arakawa
Christian Hess
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of CR20230309A publication Critical patent/CR20230309A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo multiespecífico que comprende uno o dos dominios de unión, que se unen específicamente a IL-4R (IL4R-BDs), y uno o dos dominios de unión, que se unen específicamente a IL-31 (IL31-BDs), en el cual el anticuerpo multiespecífico comprende una región Fc de inmunoglobulina. La presente invención también se refiere a ácidos nucleicos que codifican para dicho anticuerpo multiespecífico, vector(es) que comprende(n) dichos ácidos nucleicos, célula(s) hospedera(s) que comprende(n) dichos ácidos nucleicos o dicho(s) vector(es), y a un método para producir dicho anticuerpo multiespecífico. De manera adicional, la presente invención se refiere a composiciones farmacéuticas que comprenden dicho anticuerpo multiespecífico y a métodos de uso de las mismas.
CR20230309A 2020-12-23 2021-12-23 ANTICUERPOS MULTIESPECÍFICOS QUE TIENEN ESPECIFICIDAD PARA IL-4R e IL-31 CR20230309A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20216957.9A EP4019547A1 (en) 2020-12-23 2020-12-23 Multispecific antibodies having specificity for il-4r and il-31
PCT/EP2021/087561 WO2022136669A1 (en) 2020-12-23 2021-12-23 Multispecific antibodies having specificity for il-4r and il-31

Publications (1)

Publication Number Publication Date
CR20230309A true CR20230309A (es) 2023-10-09

Family

ID=73857084

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230309A CR20230309A (es) 2020-12-23 2021-12-23 ANTICUERPOS MULTIESPECÍFICOS QUE TIENEN ESPECIFICIDAD PARA IL-4R e IL-31

Country Status (16)

Country Link
EP (2) EP4019547A1 (es)
JP (1) JP2024501811A (es)
KR (1) KR20230125238A (es)
CN (3) CN116848134A (es)
AU (1) AU2021405058A1 (es)
CA (1) CA3205036A1 (es)
CL (1) CL2023001888A1 (es)
CO (1) CO2023009615A2 (es)
CR (1) CR20230309A (es)
DO (1) DOP2023000130A (es)
EC (1) ECSP23053070A (es)
IL (1) IL303174A (es)
MX (1) MX2023007533A (es)
PE (1) PE20240802A1 (es)
TW (1) TW202241966A (es)
WO (1) WO2022136669A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024002072A (es) 2021-08-23 2024-05-20 Regeneron Pharma Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
MX2024006053A (es) 2021-12-30 2024-07-29 Regeneron Pharmaceuticals Inc Metodos para atenuar la marcha atopica administrando un antagonista de il-4/il-13.
TW202421660A (zh) 2022-07-08 2024-06-01 美商再生元醫藥公司 藉由投與il-4r拮抗劑來治療嗜伊紅性食道炎的方法
WO2024061279A1 (en) * 2022-09-22 2024-03-28 Biosion Inc. Recombinant bispecific antibodies targeting tslp and il4r
WO2024097714A1 (en) 2022-11-01 2024-05-10 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist
WO2024112935A1 (en) 2022-11-23 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for improving bone growth by administering an il-4r antagonist
WO2024206341A1 (en) 2023-03-27 2024-10-03 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003301882A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
MX2009002242A (es) * 2006-09-01 2009-03-13 Zymogenetics Inc Secuencias de region variable de anticuerpos monoclonales contra il-31 y metodos de uso.
SG10201701798TA (en) 2012-09-07 2017-04-27 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
CN110746507B (zh) * 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用

Also Published As

Publication number Publication date
PE20240802A1 (es) 2024-04-18
CO2023009615A2 (es) 2023-08-28
CL2023001888A1 (es) 2023-12-15
CN116940596A (zh) 2023-10-24
AU2021405058A1 (en) 2023-06-29
ECSP23053070A (es) 2023-08-31
CN116888151A (zh) 2023-10-13
MX2023007533A (es) 2023-09-19
WO2022136669A1 (en) 2022-06-30
KR20230125238A (ko) 2023-08-29
DOP2023000130A (es) 2023-09-15
IL303174A (en) 2023-07-01
EP4019547A1 (en) 2022-06-29
AU2021405058A9 (en) 2024-09-26
CA3205036A1 (en) 2022-06-30
CN116848134A (zh) 2023-10-03
TW202241966A (zh) 2022-11-01
JP2024501811A (ja) 2024-01-16
EP4267613A1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
CR20230309A (es) ANTICUERPOS MULTIESPECÍFICOS QUE TIENEN ESPECIFICIDAD PARA IL-4R e IL-31
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
MX2023009022A (es) Anticuerpos multiespecificos con especificidad para ror1 y cd3.
EA202092735A1 (ru) Антагонизирующее cd73 антитело
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
NZ717429A (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2013078455A3 (en) Proteomic identification of antibodies
MX2022010665A (es) Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
SA522440646B1 (ar) أجسام مضادة ترتبط بـ siglec15 واستخداماتها
BRPI0607757A2 (pt) anticorpo, composição, imunoconjugado, molécula bi-especìfica, molécula de ácido nucleico isolado, vetor de expressão, célula hospedeira, hibridoma, método para preparar um anticorpo anti-psma, e, usos de um anticorpo, ou porção de ligação a antìgeno do mesmo
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
BR112021016955A2 (pt) Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
MX2021012962A (es) Anticuerpo monoclonal que se une especificamente a gitr.
ZA202201464B (en) Anti-tigit antibodies and application thereof
Babrak et al. Identification and verification of hybridoma-derived monoclonal antibody variable region sequences using recombinant DNA technology and mass spectrometry
WO2023202672A9 (en) Antibodies targeting sirp-alpha and uses thereof
MX2021010281A (es) Proteinas de enlace a antigenos que se enlazan al bcma.
ZA202210624B (en) Anti-cd137 construct and use thereof
MX2024006968A (es) Anticuerpos cdh17 y metodos de tratamiento del cancer.
MX2024003355A (es) Anticuerpos anti-cd3.
ZA202210626B (en) Anti-cd137 constructs, multispecific antibody and uses thereof
MX2023007583A (es) Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.
ZA202308896B (en) Antibodies binding trop2 and uses thereof